Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer

Bibliography

• POUND CR, PARTIN AW, EISENBERGER MA et al.: Natural history of progression after PSA elevation following radical prostatectomy. "AMA (1999) 281(7):1591–1597.
   PubMedGoogle Scholar
• ••The Brady Urological Institute outcomeswith CaP progression after PSA recurrence.
   Google Scholar
• JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics, 2002. Ca. Cancerj Gin. (2002) 52:23–47.
   PubMed Web of Science ®Google Scholar
• •Current US cancer statistics.
   Google Scholar
• GREENLEE RT, MURRAY T, BOLDEN S et al.: Cancer statistics 2000. Can. Cancer Gin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• •CaP trends in the US over the past 10 years.
   Google Scholar
• CUPP MR, BOST WICK DG, MYERS RP et al.: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol. (1995) 153:1543–1548.
   PubMed Web of Science ®Google Scholar
• •Prostate biopsy results are not a direct correlation to the amount of CaP in a specimen.
   Google Scholar
• CANTRELL BB, DE KLERK DP, EGGLESTON JC et al.: Pathologic factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. Urol. (1981) 125:516–520.
   Google Scholar
• •High Gleason grade CaPs portend a worse prognosis independent of stage.
   Google Scholar
• SOGANI PC, ISRAEL A, LIEBERMAN PH et al.: Gleason grading and prostate cancer: a predictor of survival. Urology (1995) 25:223–227.
   Google Scholar
• •High grade cancers portend a worse outcome compared to lower grade cancers.
   Google Scholar
• PONTES JE, WAJSMAN Z, HUBEN RP et al.: Prognostic factors in localized prostate cancer.' Urol. (1985) 134:1137–1139.
   PubMed Web of Science ®Google Scholar
• •Pathological stage and grade affect prognosis in CaP.
   Google Scholar
• HUTCH JA, FISHER R: Continence after radical prostatectomy. Br. J. Urol. (1968) 40:62–67.
   PubMedGoogle Scholar
• •Incontinence can be an unfortunate outcome after RR
   Google Scholar
• FINKLE AL, TAYLOR SP: Sexual potency after radical prostatectomy. Urol. (1981) 125:350–352.
   Google Scholar
• •Sexual function was poorly maintained after surgery before the anatomy was further defined.
   Google Scholar
• PETER PC: Complications of radical prostatectomy and lymphadenectomy. Urol. Clin. North Ana. (1988) 15:219–221.
   PubMedGoogle Scholar
• •The major risks of RP were better defined.
   Google Scholar
• WALSH PC, DONKER PJ: Impotence following radical prostatectomy: insight into aetiology and prevention. J. Urol (1982) 128:492–497.
   PubMed Web of Science ®Google Scholar
• •Landmark article illustrating the neurovascular anatomy involved in preserving sexual function after RE
   Google Scholar
• CATALONA WJ, MONTIE JE, SKINNER DG: The outlook of preserving continence and potency during radical prostatectomy. Contemp. Urol (1995) 6(5):18–28.
   Google Scholar
• •Article illustrating that nerve-sparing RP is reproducible.
   Google Scholar
• LING CC: Permanent implants using AU-198, Pd-103, 1-125: radiobiological considerations based on the linear quadratic model. Irk. I Radiat. Oncol. Biol. Phys. (1992) 23:81–87.
   PubMedGoogle Scholar
• •First article reintroducing the use of brachytherapy in CaP treatment.
   Google Scholar
• STOCK RG, STONE NN, DEWYNGAERTJK et al.: Prostate-specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer. Cancer (1996) 77:2386–2392.
   PubMed Web of Science ®Google Scholar
• •Initial results of the clinical use of brachytherpy in the treatment of CaP.
   Google Scholar
• SHIPLEY WU, ZIETMAN AL, HANKS GE et al.: Treatment related sequealle following external beam radiation for prostate cancer: a review with an update in patients with clinical stages Ti and T2../. Urol. (1994) 152:1799–1805.
   Google Scholar
• ••Complications of XRT in the treatment ofCaP.
   Google Scholar
• FORMAN JD, MEETZE K, PONTES E et al.: Therapeutic irradiation for patients with an elevated postprostatectomy prostate-specific antigen level. " Urol (1997) 158:1436–1439.
   Google Scholar
• •Clinical evaluation of postprostatectomy radiotherapy for isolated PSA elevation.
   Google Scholar
• CADDEDU JA, PARTIN AW, DEWEESE TL et al.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. Urol (1998) 159:173–178.
   Google Scholar
• •Complications of salvage radiotherapy.
   Google Scholar
• PISANSKY TM, KOZELSKY TF, MYER RP et al.: Radiotherapy for isolated prostate-specific antigen elevation after radical prostatectomy for prostate cancer. J. Urol. (2000) 163:845–850.
   PubMed Web of Science ®Google Scholar
• •Latest study illustrating the benefits and complications of salvage radiotherapy.
   Google Scholar
• THOMPSON IM, ROUNDER JB, SPENCE CR et al.: Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer (1988) 61:1464–1466.
   PubMedGoogle Scholar
• •Landmark article describing the initial use of salvage prostatectomy.
   Google Scholar
• VAIDYA A, SOLOWAY MS: Salvage radical prostatectomy for radio-recurrent prostate cancer: morbidity revisited. J. Urol. (2000) 164(6):1998–2001.
   PubMedGoogle Scholar
• •Morbidity of salvage RE
   Google Scholar
• LILIJA H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. (1985) 76:1899-1903. First functional explanation for the activity of PSA.
   Google Scholar
• STAMEY TA, YANG N, HAY AR et al: Prostate-specific antigen as a serum tumour marker for adenocarcinoma of the prostate. N Engl. J. Med. (1987): 317:909–916.
   PubMed Web of Science ®Google Scholar
• ••Landmark article describing the use of PSAas a tumour marker for CaP.
   Google Scholar
• VAN STRAALEN JP, BOSSENS MM, DE REIJKE TM et al.: Biological half-life of prostate-specific antigen after radical prostatectomy. Ear: I Clin. Chem. Clin. Biochem. (1994) 32:53–55.
   Google Scholar
• •The pharmacokinetics of serum PSA.
   Google Scholar
• POUND CR, PARTIN AW, EPSTEIN JI et al.: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol. Clin. North Am. (1997): 24:395–406.
   PubMed Web of Science ®Google Scholar
• •Describes rare cases of CaP recurrence without a PSA elevation.
   Google Scholar
• PARTIN AW, KATTAN MW, SUBONG EN et al: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. "AMA (1997) 277:1445–1451.
   PubMed Web of Science ®Google Scholar
• •Pre-treatment nomograms describing the ability to contain cancer within the prostate depending on clinical stage and PSA.
   Google Scholar
• COX JD, GALLAGHER MJ, HAMMOND EH et al: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy: American Society for Therapeutic Radiology and Oncology Consensus Panel. .1 Clin. Oncol. (1999) 17:1155–1159.
   PubMed Web of Science ®Google Scholar
• •ASTRO consensus statement defining PSA failures following radiotherapy.
   Google Scholar
• CRITZ FA, LEVINSON K, WILLIAMS WH et al.: Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J. Clin. Oncol. (1996) 14:2893–2900.
   PubMed Web of Science ®Google Scholar
• •Discusses the importance of 0.5 ng/ml as a PSA cutoff for cure for CaP after radiotherapy.
   Google Scholar
• KATTAN MW, ZELEFSKY MJ, KUPELIAN PA et al.: Pretreatment nomogram for predicting the outcome of 3Dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. (2000) 18:3352–3359.
   PubMed Web of Science ®Google Scholar
• •Pretreatment risks of PSA failure following radiotherapy for CaP.
   Google Scholar
• HUGGINS C, HODGES CV: The effects of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:942–947.
   Google Scholar
• ••Nobel prize winning experiments ofandrogen deprivation.
   Google Scholar
• WALSH PC, MADDEN JD, HARROD MJ et al: Familial incomplete male pseudohermanphroditism, Type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl. J. Med. (1974) 291:944–949.
   PubMed Web of Science ®Google Scholar
• •5-a-reductase deficiency phenotype - first case described in the literature.
   Google Scholar
• NEELON FA: Adrenal physiology and pharmacology. Urol. Clin. of North Am. (1977) 4:179–192.
   PubMedGoogle Scholar
• •Description of adrenal physiology.
   Google Scholar
• VERMEULEN A, ANDO S: Metabolic clearance rate and interconversion of androgens and the influence of the androgen fraction. I Clin. Endocrin. Metab. (1979) 48:320–326.
   PubMed Web of Science ®Google Scholar
• •Metabolic influence and conversion of androgens.
   Google Scholar
• WOLLESEN F, SWERDLOFF RS, PETERSON M et al: Testosterone modulation of pituitary response to LRH: differential effects of lutenizing hormone and follicle-stimulating hormone. J. Clin. Invest. (1975) 53:85A.
   Google Scholar
• •Describes the positive-inhibition of FSH and LH.
   Google Scholar
• CROWLEY WF JR, FILICORI M, SPRATT DI et al.: The physiology of gonadotropin releasing hormone secretion in men and women. Rec. Frog. Horm. Res. (1985): 41:473–531.
   PubMedGoogle Scholar
• •Description of LHRH in humans.
   Google Scholar
• MARSHALL JC, ANDERSON DC, FRASIER TR et al.: Human lutenizing hormone in man: studies of metabolism and biological action. Endocrinology(1973): 56:431–439.
   Google Scholar
• •Functions of LH.
   Google Scholar
• MATSUMOTO AM, KARPAS AE, BREMNER WJ: Chronic hCG administration in normal men: evidence that FSH is necessary for the maintenance of quantitatively normal spermatogenesis in man. J. Clin. Endocrinol. (1986) 62:1184–1192.
   PubMed Web of Science ®Google Scholar
• •Importance of FSH on spermatogenesis.
   Google Scholar
• SWERDLOFF RS, WALSH PC: Testosterone and estradiol suppression of LH and FSH in adult male rats: duration of castration, duration of treatment and combined treatment. Acta. Endocrinol. (1973) 73:11-21. Effects of castration and oestrogen administration on FSH and LH levels.
   Google Scholar
• YING SY, CZVIK J, BECKER A et al.: Secretion of follicle-stimulating hormone and production of inhibin are reciprocally related. Proc. Natl. Acad. Sci. (1987) 84:4631–4635.
   PubMedGoogle Scholar
• •First description of the protein inhibin on FSH feedback.
   Google Scholar
• LIN BJT, CHEN K, CHEN M et al.: The time for serum testosterone to reach castrate levels after bilateral orchiectomy or oral oestrogen in the management of metastatic prostate cancer. Urology (1994) 43:834–837.
   PubMedGoogle Scholar
• •Time to reach castrate testosterone levels following castration.
   Google Scholar
• EZRIN C, BRIANT TD, FIRESTONE G et al.: The endocrine aspects of trans-sphenoidal hypophysectomy. Can. Med. Assoc. J. (1967) 97:72–75.
   PubMedGoogle Scholar
• •Transphenoidal surgery and the endocrine palliation of CaP.
   Google Scholar
• GOTTESMAN L: Technique of bilateral palliative adrenalectomy. Surg., Gyn. Obstet. (1967) 125:121–122.
   PubMedGoogle Scholar
• •Palliative adrenalectomy described for palliation of advanced CaP.
   Google Scholar
• BOYNS AR, COLE EN, PHILLIP ME et al.: Plasma Prolactin, CH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens. Ear: J. Cancer (1974) 10:445–449.
   PubMed Web of Science ®Google Scholar
• •Description of the effects of oestrogens on gonadotropin levels.
   Google Scholar
• BYAR DP, CORLE DK: Hormone therapy for prostate cancer: results of the VACURG studies. NCI Monograms (1988) 1:553.
   Google Scholar
• •Description of the VACURG study.
   Google Scholar
• KENT JR, BISCHOFF AJ, ARDUVINO LJ et al.: oestrogen dosage and suppression of testosterone levels in patient with prostatic carcinoma. J. Urol. (1973) 109:858–860.
   PubMedGoogle Scholar
• •Safe dosage for diethylstilbestrol in men undergoing androgen deprivation.
   Google Scholar
• SCHERR D, PITTS WR, VAUGHAN ED et al.: Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J. Urol. (2002) 167:535–538.
   PubMed Web of Science ®Google Scholar
• •Diethylstilbestrol therapy showing protection against osteoporosis.
   Google Scholar
• HANASH KA, TAYLOR WF, GREEN LF et al.: Relationship of estrogen therapy for carcinoma of the prostate to atherosclerotic cardiovascular disease: a clinicopathologic study. J. Urol. (1970) 103:467–470.
   PubMed Web of Science ®Google Scholar
• •Case studies of cardiovascular mortality of diethylstilbestrol.
   Google Scholar
• GELLER J, FRUCHTMAN B, NEWMAN H et al.: Effects of progestational agents on carcinoma of the prostate. Cancer Chemo. Rep.(1967) 51(1):41–46.
   PubMedGoogle Scholar
• •Androgen deprivation using progestins.
   Google Scholar
• LABRIE C, CUSAN L, PLANTE M et al.: Analysis of the androgenic activity of synthetic 'progestins'currently for the treatment of prostate cancer. J. Steroid Biochem. (1987) 28:379–384.
   PubMedGoogle Scholar
• •The escape phenomenon of progestins.
   Google Scholar
• ASTEDT B: New aspects of the thrombogenic effects of oral contraceptives. Amer. Heart J. (1975) 90:1–3.
   PubMedGoogle Scholar
• •Thrombogenic effects of progestins.
   Google Scholar
• LEAU I, MERK FB, LEE KF et al: Prolactin receptor expression in the developing human prostate and in the hyperplastic, dysplastic and neoplastic lesions. Amer: J. Path. (1999) 154:863–870.
   PubMedGoogle Scholar
• •Prolactin receptors in CaP.
   Google Scholar
• GRAYHACK JT, BUNCE PL, KEARNS JW et al.: Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp. (1955) 76:154–163.
   Google Scholar
• •Animal studies of prolactin on the ventral rat prostate.
   Google Scholar
• FARNSWORTH WE, SLAUNWHITE WR, SHARMA M et al.: Interaction of prolactin and testosterone in the human prostate. Urol. Res. (1981) 9:79–88.
   PubMedGoogle Scholar
• •Evidence against prolactin antagonist activity in CaP.
   Google Scholar
• SCHALLY AV, ARIMURA A, BABA Y et al.: Isolation and properties of the FSH and LH releasing hormone. Biochem. Biophy. Res. Commun. (1971) 43:393–399.
   PubMed Web of Science ®Google Scholar
• •LHRH physiology.
   Google Scholar
• SANTEN KJ, BARDIN CW: Episodic lutenizing hormone in man: Pulse analysis, clinical interpretation, physiologic mechanisms. j Clin. Invest. (1973) 52:2617.
   PubMed Web of Science ®Google Scholar
• •Physiological studies showing the pulsatile release of LHRH.
   Google Scholar
• FIET J, DOVE J, LE GO A et al.: Multivariate analysis of plasma hormones in patient s with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. Prostate (1993) 23:291–313.
   Google Scholar
• •Details of LHRH agonists and the time to reach castrate testosterone levels.
   Google Scholar
• THOMPSON IM, ZEIDMAN EJ, RODRIGUEZ FR: Sudden death due to disease flare with lutenizing hormone-releasing agonists therapy for carcinoma of the prostate. Urol. (1990) 144:1479–1480.
   Web of Science ®Google Scholar
• •The flare phenomenon in LHRH agonist usage in CaP.
   Google Scholar
• FOWLER JE, FLANAGAN M, GLEASON DM et al.: Evaluation of an implant that delivers leuprolide for one year palliative treatment of prostate cancer. Urol. (2000) 55:639–642.
   PubMed Web of Science ®Google Scholar
• •The leuprolide implant now available in the US.
   Google Scholar
• SHARIFI R, SOLOWAY M, LEUPROLIDE STUDY GROUP: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol. (1990) 143:63–71.
   Google Scholar
• •Studies of the adverse effects of LHRH agonists.
   Google Scholar
• STRICKER HJ: Lutenizing hormone- releasing hormone antagonists in prostate cancer. Urology (2001) 58(2, Suppl. 1):24–27.
   Google Scholar
• •Review of LHRH antagonist therapy for the treatment of CaP.
   Google Scholar
• MOLINEAU CT, SLUSS PM, BREE MP et al.: Suppression of plasma testosterone by abarelix a new potent LHRH antagonist. Urol. (1988) 2:265–268.
   Google Scholar
• •Experimental evidence of androgen deprivation using abarelix.
   Google Scholar
• TRACHTENBERG J, GITTLEMAN M, CHRISTOPHER S et al.: A Phase III, multicenter, open-label, randomized study of abarelix versus leuprolide plus daily antiandrogens in men with prostate cancer. .1 Urol. (2002) 167:1670–1674.
   Google Scholar
• BRINKMAN AO, JENSTER G, RIS-STALPER C et al.: AR Mutation. J. Steroid Biochem. Molec. Biol. (1995) 53:443–448.
   PubMedGoogle Scholar
• •Mechanism of action of non-steroidal anti-androgens.
   Google Scholar
• HUANG JK, BARTSCH W, VOIGHT KD: Inhibition of antiandrogens (cyproterone acetate) with the androgen receptor systems and its biological action in the rat ventral prostate. Acta. Endocrinol (1985) 109:569–576.
   PubMedGoogle Scholar
• •Mechanism of action of oral anti-androgens.
   Google Scholar
• DEKERNION JN, MURPHY GP, PRIORE R: Comparison of flutamide to emcyt in hormone-refractory metastatic prostate cancer. Urology (1988) 31(4):312–317.
   PubMedGoogle Scholar
• •Flutarnide trials for the treatment of CaP.
   Google Scholar
• HARNOIS C, MALENFANT M, DUPONT A et al: Ocular toxicity of antiandrogens in patients treated for prostatic cancer. Br. .1 Ophthamol (1986) 70:471–473.
   PubMedGoogle Scholar
• •Case report of prolonged night-blindness with oral anti-androgen usage.
   Google Scholar
• SEIGNEUR J, TRECHOT PF, HUBERT J et al.: Pulmonary complications of hormone treatment in prostate carcinoma. Chest (1988) 93:1106.
   PubMed Web of Science ®Google Scholar
• •Case reports of pulmonary fibrosis associated with non-steroidal anti-androgens.
   Google Scholar
• KUCUK O, FISHER E, MOMPOUR CM et al.: Phase II trial of bicalutamide in patient with advanced prostate cancer in whom conventional hormonal therapy failed: a South West Oncology Group study (SWOG 9235). Urol. (2001) 58:53–58.
   PubMed Web of Science ®Google Scholar
• •Important clinical trial showing the continuing anti-androgen effect of bicalutamide after failure of conventional androgen deprivation.
   Google Scholar
• DE VOOGT HJ, SMITH P, MAVONE-MACALUSO et al.: Cardiovascular side effects of DES, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostate cancer: results form the EORTC trial 30761 and 30762. J. Urol. (1986) 135:303–307.
   PubMed Web of Science ®Google Scholar
• •EORTC trial comparing the cardiovascular effects of cyproterone acetate to diethylstilbestrol.
   Google Scholar
• RADLMAIRE A, BORMACHER K, NEUMANN F: Hot flashes: mechanism and prevention. EORTC GU group monograph 8: treatment of prostate cancer-facts and controversies. Alan R Liss (Ed.), New York, (1990), pp131–140.
   Google Scholar
• •Study showing cyproterone acetate protection against hot flashes.
   Google Scholar
• LOWE FC, SOMER WJ: The use of ketoconazole in the emergency management of disseminated intravascular coagulopathy due to metastatic prostate cancer. J Urol. (1987) 137:1000–1002.
   PubMed Web of Science ®Google Scholar
• •Hallmark study showing the emergent usage of ketoconazole for the treatment of life-threatening CaP metastasis.
   Google Scholar
• WHITE MC, KENDAL-TAYLOR P: Adrenal hypofunction in patients taking Ketoconazole. Lancet (1985) 1:44–45.
   PubMedGoogle Scholar
• •Case report offside effects associated with prolonged ketoconazole usage.
   Google Scholar
• HASSELLUND S, SANDERS S, NORMANN N: Side effects of Ketoconazole therapy in advanced prostate cancer. A case report. Progress M Clin. and Biol. Res. (1987) 242-A:299–300.
   Google Scholar
• •Case report of hypoadrenalism associated with prolonged ketoconazole usage.
   Google Scholar
• ROBINSON MR: Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after six years. Br. J. Um]. (1980) 52:328–329.
   Google Scholar
• •Review of the mechanism of action and side effects of arninoglutethimide used for the treatment of CaP.
   Google Scholar
• BRUFSKY A, FONTAINE-ROTHE P, BERLANE K et al.: Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology (1997) 49:913–920.
   PubMed Web of Science ®Google Scholar
• •Potency-sparing androgen deprivation.
   Google Scholar
• ORNSTEIN DK, RAO GS, JOHNSON B et al.: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology (1996) 48(6):901–5.
   PubMedGoogle Scholar
• •Report of potency-sparing androgen deprivation.
   Google Scholar
• ORNSTEIN DK, SMITH D, ANDRIOLE G: Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology (1998) 52:1094–1097.
   PubMed Web of Science ®Google Scholar
• •Finasteride mechanism of action.
   Google Scholar
• CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl. J. Med. (1989) 321:419–424.
   PubMed Web of Science ®Google Scholar
• •Case study showing an advantage of combined androgen deprivation.
   Google Scholar
• EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl. J. Med. (1998) 339:1036–1042.
   PubMed Web of Science ®Google Scholar
• ••Case study definitively showed noadvantage of combined androgen deprivation.
   Google Scholar
• AKAKURA K, BRUCHOVSKY N, GOLDENBERG SL et al: Effects of intermittent androgen suppression on androgen-dependent tumours. Cancer (1993) 71:2782–2790.
   PubMed Web of Science ®Google Scholar
• •Animal study showing tumour suppression using intermittent androgen deprivation.
   Google Scholar
• BRUCHOVSKY N, RENNIE PSA, COLDMAN AJ et al.: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. (1990) 50:2275–2282.
   PubMed Web of Science ®Google Scholar
• •Animal study showing tumour suppression using intermittent androgen deprivation.
   Google Scholar
• KLOTZ LH, HERR HW, MORSE MJ et al.: Intermittent endocrine therapy for advanced prostate cancer. Cancer (1986) 58:2546–2550.
   PubMed Web of Science ®Google Scholar
• ••A clinical study of successful intermittentandrogen deprivation.
   Google Scholar
• KELLY WK, SCHER HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Um]. (1993) 149(3):607–609.
   Google Scholar
• •Case reports of flutamide withdrawal.
   Google Scholar
• DUPONT A, GOMEZ JL, CUSAN L, KOUTSILIERIS M, LABRIE F: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Um]. (1993) 150(3):908–913.
   Google Scholar
• •Case reports of flutamide withdrawal.
   Google Scholar
• SMALL EJ, SRINIVAS S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer (1995) 76(8):1428–1434.
   Google Scholar
• •Case reports of flutamide withdrawal.
   Google Scholar
• SMALL EJ, CARROLL PR: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology (1994) 43(3):408–10.
   PubMed Web of Science ®Google Scholar
• •Case reports of bicalutarnide withdrawal.
   Google Scholar
• NIEH PT: Withdrawal phenomenon with the antiandrogen casodex. Um]. (1995) 153(3 Pt 2):1070–1072.
   Google Scholar
• •Case reports of bicalutarnide withdrawal.
   Google Scholar
• GREGORY CW, JOHNSON RT JR, MOHLER JL et al.: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. (2001) 61(7):2892–2898.
   PubMed Web of Science ®Google Scholar
• •Experimental evidence of the promiscuous androgen receptor.
   Google Scholar
• MESSING EM, MANOLA J, SAROSDY M et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with positive lymph node prostate cancer. N Engl. J. Med. (1999) 341:1781–1788.
   PubMed Web of Science ®Google Scholar
• ••Randomised clinical trial comparingimmediate androgen deprivation versus observation.
   Google Scholar
• ZINCKE H, BERGSTRALH EJ, LARSON-KELER JJ et al.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal therapy. Evidence for favorable survival in patients with DNA diploid tumours. Cancer (1992) 70:311–323.
   Google Scholar
• ••Case report of patients given immediateandrogen deprivation for lymph node positive disease after RE
   Google Scholar
• WALSH PC, DEWEESE TL, EISENBERGER MA et al.: A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J. Um]. (2001) 166:508–516.
   Google Scholar
• •Arguments for and against the usage of immediate androgen deprivation.
   Google Scholar
• FELDMAN BJ AND FELDMAN D: The development of androgen-independent prostate cancer. Nature Rev (2001) 1:34–44.
   Google Scholar
• •Review of the mechanisms possible for androgen deprivation.
   Google Scholar
• BLOCKARD CE, BYARS BP, JORDAN WP: Orchiectomy for advanced prostate carcinoma. A reevaluation. Urology (1973) 1:553.
   Google Scholar
• •VACURG studies of androgen deprivation.
   Google Scholar
• BYARS DP: The veterans administration cooperative Urological research group studies of cancer of the prostate. Cancer (1973) 32:1126.
   PubMedGoogle Scholar
• •VACURG studies using diethylstilbestrol for immediate versus delayed androgen deprivation for the treatment of advanced CaP.
   Google Scholar
• CHRISTENSEN MM, AAGAARD J, MADSEN PO: Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur). Frog. Clin. Biol. Res. (1990) 359:4–24.
   Google Scholar
• ••Critical review of the VACURG studies.
   Google Scholar
• THE MEDICAL RESEARCH COUNCIL PROSTATE CANCER WORKING PARTY INVESTIGATORS GROUP: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council. Br. J. Um]. (1997) 79:235–246.
   Google Scholar
• ••Medical Research Council studycomparing immediate versus delayed androgen deprivation for the treatment of advanced CaP.
   Google Scholar
• BOLLA M: Cancer of the prostate: therapeutic trials in 1985. Bull Cancer (1986) 73:74–80.
   PubMedGoogle Scholar
• •EORTC trials of neoadjuvant androgen deprivation in radiotherapy for CaP. Expert Op/n. Pharmacother. (2002) 3(6)
   Google Scholar
• BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl. Med. (1997) 337:295–300.
   PubMed Web of Science ®Google Scholar
• •EORTC trials of LHRH agonists with radiotherapy for CaP.
   Google Scholar
• GUPTA S, SRIVASTARA M, AHMAD N et al.: Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73–78.
   PubMed Web of Science ®Google Scholar
• ••Landmark study showing theoverexpression of COX-2 in CaP.
   Google Scholar
• TJANDRAWMATA RR, HUGHES-FULFORD M: Upregulation of cyclooxygenase-2 by-product prostaglandin E2. Adv. Exp. Med. Biol. (1997) 407:163–170.
   PubMedGoogle Scholar
• •Upregulation of COX-2 causes the upregulation of PGE2.
   Google Scholar
• LIU XH, YAO S, KIRSCHENBAUM A et al.: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bc1-2 expression in LNCaP cells. Cancer Res. (1998) 58:4245–4249.
   PubMed Web of Science ®Google Scholar
• ••Important basic science showing therelationship between COX-2 and bc/-2 expression.
   Google Scholar
• BONKHOFF H, FIXEMER T, REMBERGER K: Relationship between bc1-2, cell proliferation and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate (1998) 34:251–258.
   PubMed Web of Science ®Google Scholar
• •Effects of bc/-2expression and cell apoptosis in CaP.
   Google Scholar
• LIU XH, KIRSCHENBAUM A, YAO S et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and growth of prostate cancer in vivo. Urol. (2000) 164:820–825.
   Web of Science ®Google Scholar
• •Experimental evidence linking COX-2 inhibition to decreased angiogenesis.
   Google Scholar
• LOPRINZI CL, SLOAN JA, PEREZ EA et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol (2002) 20(6):1578–1583.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, SPITZWEG C, BATEMAN AR et al.: Gene therapy for prostate cancer: current status and future prospects. Urol. (2001) 166: 1220–1233.
   Google Scholar
• •Review of gene therapy in the treatment of CaP.
   Google Scholar
• ZANG WW: Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Then (1999) 6:113.
   PubMedGoogle Scholar
• •Adenoviral vectors used for CaP gene therapy.
   Google Scholar
• CURIEL DT: Strategies to adapt adenoviral vectors for targeted delivery. Ann. NY Acad. Sci. (1999) 886:158
   PubMed Web of Science ®Google Scholar
• FINK DJ, GLORIOSO JC: Engineering herpes simplex virus vectors for gene transfer to neurons. Nat. Med. (1997) 3:357.
   PubMed Web of Science ®Google Scholar
• •HSV vectors used for CaP gene therapy.
   Google Scholar
• PUHLMAN M, BROWN CK, GRANT M et al.: M vaccinia as a vector for tumour directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Then (2000) 7:66.
   PubMed Web of Science ®Google Scholar
• •M vaccinia viral vectors used for CaP gene therapy.
   Google Scholar
• HUBER PE, PFISTERER P: In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumour R3327-AT1 is enhanced by focused ultrasound. Gene Ther. (2000) 7:1516.
   PubMed Web of Science ®Google Scholar
• •Experimental modal of gene transfection in the Dunning model.
   Google Scholar
• FYNAN EF, WEBSTER RG, FULLER DH et al.: DNA vaccines: protective immunizations by parenteral, mucosal and gene inoculations. Proc. Nati Acad. Sci. (1993) 90:11478.
   PubMed Web of Science ®Google Scholar
• •Use of DNA vaccines in gene therapy.
   Google Scholar
• FELGNER PL, GADEL TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Nati Acad. Sci. (1987) 84:7413.
   PubMed Web of Science ®Google Scholar
• •Article describes liposomal transfection of DNA into cells.
   Google Scholar
• LI S, HUANG L: Nonviral gene therapy: promises and challenges. Gene Ther. (2000) 7:31.
   PubMed Web of Science ®Google Scholar
• •Article that describes alternative methods of gene transfection into cells without the usage of viral vectors.
   Google Scholar
• MURPHY GP, TJOA BA, SIMMONS SJ et al.: Phase II prostate cancer vaccine trial: report involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 39:54–59.
   PubMed Web of Science ®Google Scholar
• ••Irnmunotherapy trial showing a responsein patients using pulsed dendritic cells.
   Google Scholar
• PEGRAM MD, LIPTON A, HAYES DF et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antip185Her-2/neu monoclonal antibodies and cisplatin in patients with Her-2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. Clin. Onc. (1998) 16 (8):2659–2671.
   Google Scholar
• •Herceptin usage in metastatic cancer.
   Google Scholar
• ISRAELI RS, POWELL CT, FAIR WR et al.: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. (1993) 53 (2):227–230.
   PubMed Web of Science ®Google Scholar
• •PSMA isolation, characterisation and cloning.
   Google Scholar
• WRIGHT GL, GROB BM, HALEY C et al.: Upregulation of prostate-specific membrane antigen after androgen deprivation therapy. Urology (1996) 48(2):326–334.
   PubMed Web of Science ®Google Scholar
• •Experimental evidence of upregulation of PSMA in advanced CaP.
   Google Scholar
• LIU H, MOY P, KIM S et al.: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular endothelium. Cancer Res. (1997) 57(17):3629–3634.
   PubMed Web of Science ®Google Scholar
• •Experimental evidence of the antiturnour effects of monoclonal PSMA antibodies used to treat CaP.
   Google Scholar